Status:
COMPLETED
The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver
Lead Sponsor:
Rawi Hazzan
Collaborating Sponsors:
HaEmek Medical Center, Israel
Conditions:
Fatty Liver, Nonalcoholic
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is involved in transporting fatty acids across the mitochondrial membrane, it could be an important component in tr...
Detailed Description
A phase 3, randomized, double blind placebo controlled study that evaluate the efficacy of L-Carnitine and Magnesium as a treatment for fatty liver, 60 eligible patients with a diagnosis of NAFDL will...
Eligibility Criteria
Inclusion
- Male and Female between the age 18 and 75.
- Patients with diagnosis of NAFLD when other etiologies for fatty liver were ruled out.
- Patients who sign a confirmed consent.
Exclusion
- Patients with liver failure.
- Patients with acute or chronic renal failure ( CCT\< 50 ml/min or creatinine \> 1.5 mg/dl)
- Patients with congestive heart failure (NYHA 3-4)
- Patients with active cancer
- Patients on Estrogen therapy, MTX, chloroquine.
- Patients with a history of Hypothyroidism or Cushing disease.
- Patients who received TPN in the past 6 months.
- Patients with chronic liver disease, A1AT, Hemochromatosis, Wilson, Autoimmune, Toxic injury.
- Patients on anticoagulation therapy - Coumadin.
- Patients who use valproic acid therapy.
- Children, Pregnancy.
Key Trial Info
Start Date :
October 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2018
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03319199
Start Date
October 30 2017
End Date
July 25 2018
Last Update
August 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haemek medical center
Afula, Israel, 1834111